My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

59.35 +0.17 (+0.29%)

Streaming Delayed Price Updated: 3:59 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

28 29 Next >

Replimune Shares Surge After Early Data From Pretreated Melanoma Patients ↗

December 07, 2022

Via Benzinga

Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors ↗

December 02, 2022

Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.

Via Benzinga

Gilead's Cancer Program Notches Another Win, But It's Arcus Stock That Surges ↗

November 28, 2022

Gilead and Arcus notched another win for their cancer program on Monday. GILD stock briefly hit a four-year high as RCUS stock gapped higher.

Via Investor's Business Daily

This Congressman Just Purchased 2 Stocks Which Consistently Increase Dividends ↗

November 28, 2022

Congressman Dwight Evans (D-PA) has represented Pennsylvania's Third Congressional District since 2019, and has made over 70 trades in the past three years. His top two traded investments are Intel...

Via Benzinga

Biogen To Report Q3 Earnings: Here's What To Expect ↗

October 21, 2022

Biogen will report third-quarter 2022 results on Oct 25, before market open.

Via Talk Markets

Daily Stock Analysis: Roche Holding ↗

November 18, 2022

By my dogcatcher ideal, this is not a good time to buy Roche Holding AG shares based on their dividends for the coming year 2022-23.

Via Talk Markets

Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm ↗

November 16, 2022

Neurodegenerative disorders could mean big bucks for some biotechs.

Via Investor's Business Daily

Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says ↗

November 16, 2022

Via Benzinga

FDA Gives Emergency Use Nod To Roche's Monkeypox Test ↗

November 16, 2022

Via Benzinga

Successful Alzheimer's Data Would Have Placed Roche At Two-Year Competitive Advantage ↗

November 15, 2022

Via Benzinga

Roche Inks Second Drug Discovery Deal With Jnana Therapeutics ↗

November 15, 2022

Via Benzinga

FDA Grants Conditional Approval To First Antibody Drug Conjugate From ImmunoGen For Pretreated Ovarian Cancer ↗

November 15, 2022

Via Benzinga

Why Is Cassava Sciences (SAVA) Stock Up Today? ↗

November 14, 2022

Today's big move in Cassava Sciences and SAVA stock has many investors watching this company's trials closer than ever.

Via InvestorPlace

Eli Lilly's Twitter Fiasco Continues As Drugmaker Reportedly Pulls 'Millions' In Twitter Ads ↗

November 14, 2022

The fallout from a fake account continued Monday as Lilly reportedly pulled Twitter ads.

Via Investor's Business Daily

Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers ↗

November 14, 2022

Via Benzinga

Why Is Biogen (BIIB) Stock Up Today? ↗

November 14, 2022

Biogen (BIIB) stock is rising higher on Monday after Roche's (RHHBY) Alzheimer's drug didn't perform well in a clinical trial.

Via InvestorPlace

Roche's Alzheimer's Drug Fails In Phase 3; Here's The Fallout For Biogen, Lilly, Prothena And Others ↗

November 14, 2022

Biogen rose on Roche's Alzheimer's failure as a potential competitor drops off the map.

Via Investor's Business Daily

The OTCQB Venture Market Records 4 Months Of Consecutive Volume Increases In OTC Market Group's Most-Active List In October ↗

November 14, 2022

The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) increased by 8.13% in October — its second-largest monthly increase in 2022.

Via Benzinga

Roche's Another Alzheimer's Hopeful Flops In Phase 3 Program, Second Trial Setback Within Months ↗

November 14, 2022

Via Benzinga

Nasdaq, S&P 500 Futures Pullback At Start Of New Trading Week As Rate Fears Return To Haunt; AMD, Tesla, Biogen, Eli Lilly, JD In Focus ↗

November 14, 2022

The major U.S. index futures are pointing to a moderately lower opening on Wall Street on Monday, as optimism following a tamer inflation data gives way to apprehension. The yield on the benchmark...

Via Benzinga

Why Shares Of Eli Lilly And Biogen Are Rallying Today ↗

November 14, 2022

Shares of Biogen Inc. (NASDAQ: BIIB) and Eli Lilly & Co. (NYSE: LLY) are rallying in premarket trading on Monday despite the negative broader market sentiment.

Via Benzinga

6 ETFs That Are All You Need for Retirement ↗

October 30, 2022

These yield-producing stock and bond funds are all down less than the S&P 500 this year.

Via The Motley Fool

15 Global Psychedelics Executives To Keep An Eye On In 2022 ↗

October 28, 2022

As the global psychedelics industry booms, with companies going public, major financings being announced, and celebrities and big investors getting on board, Benzinga has decided to put together a list...

Via Benzinga

Most Active On The OTC Markets In September – A Look Back As October Comes To A Close

October 28, 2022

By Jad Malaeb, Benzinga

Via News Direct

Topics ETFs Stocks

Most Active On The OTC Markets In September – A Look Back As October Comes To A Close ↗

October 27, 2022

The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) declined by 9.62% in September – its largest decline in 2022.

Via Benzinga

Analyst Bullish On SQZ Biotech's Technology For Solving Cell Therapy Challenges ↗

October 20, 2022

Via Benzinga

Roche Posts Lower Quarterly Sales As Demand For COVID Products Slide ↗

October 18, 2022

Via Benzinga

Market Sentiment Improves Amid Earnings Season ↗

October 18, 2022

The fourth quarter started on a sour note as geopolitical tensions and recession fears triggered a risk-averse mood, but earnings season has started since then, focusing market participants’ attention...

Via Talk Markets

Week In Review: Jemicare Out-Licenses Prostate Cancer Therapy To Roche For $650 Million ↗

October 15, 2022

Deals, financings, trials and approvals on the China biotech/pharma market.

Via Talk Markets

Analyst Upgrades Biogen Citing Upcoming Conference, Competitive Readouts ↗

October 13, 2022

Stifel upgraded Biogen Inc (NASDAQ: BIIB) from Hold to Buy, saying shares have faded since positive lecanemab data in mild Alzheimer's.

Via Benzinga

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

28 29 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.